Search
Results: 29003
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK
Xinxue Liu, Alasdair PS Munro, Shuo Feng, Leila Janani, Parvinder K Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Wanwisa Dejnirattisai, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L Goodman, Christopher A Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A van der Klaauw, Jonathan Kwok, Vincenzo Libri, Martin J Llewelyn, Alastair C McGregor, Angela M Minassian, Patrick Moore, Mehmood Mughal, Yama F Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Teona Serafimova, Dinesh Saralaya, Gavin R Screaton, Sunil Sharma, Ray Sheridan, Ann Sturdy, Piyada Supasa, Emma C Thomson, Shirley Todd, Chris Twelves, Robert C Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S Nguyen-Van-Tam, Victoria Cornelius, Matthew D Snape, Saul N Faust, COV-BOOST study group
May 13, 2022
OBJECTIVES: To evaluate the persistence of immunogenicity three months after third dose boosters. METHODS: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster...
COVID-19 vaccine Fractional dose Heterologous boost Homologous boost Immunogenicity Persistence Third dose Ad26COVS1 Adult Aged Aged 80 and over Antibodies Viral BNT162 Vaccine covid-19 COVID-19 Vaccines ChAdOx1 nCoV-19 Humans Immunogenicity Vaccine Immunoglobulin G Middle Aged SARS-CoV-2 United Kingdom Viral Vaccines mRNA Vaccines
Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis.
Lourdes Ortiz-Fernández, Francisco David Carmona, Raquel López-Mejías, Maria Francisca González-Escribano, Paul A Lyons, Ann W Morgan, Amr H Sawalha, Peter A Merkel, Kenneth GC Smith, Miguel A González-Gay, Javier Martín, UK GCA Consortium, Turkish Takayasu Study Group, Vasculitis Clinical Research Consortium, IgAV Study Group, AAV Study group Spanish GCA Study Group
Apr 18, 2018
OBJETIVE: Systemic vasculitides represent a heterogeneous group of rare complex diseases of the blood vessels with a poorly understood aetiology. To investigate the shared genetic component underlying their predisposition, we...
Autoantibodies outcomes research systemic sclerosis Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Case-Control Studies Epigenesis Genetic Female Genetic Loci Genetic Predisposition to Disease Giant Cell Arteritis HLA-DQ Antigens HLA-DQ beta-Chains Humans Jumonji Domain-Containing Histone Demethylases Linkage Disequilibrium Male Phenotype Polymorphism Single Nucleotide Protein Array Analysis Systemic Vasculitis Takayasu arteritis
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST)
Alasdair PS Munro, Shuo Feng, Leila Janani, Victoria Cornelius, Parvinder K Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L Goodman, Christopher A Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A van der Klaauw, Nasir Kanji, Vincenzo Libri, Martin J Llewelyn, Alastair C McGregor, Mina Maallah, Angela M Minassian, Patrick Moore, Mehmood Mughal, Yama F Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Tanveer Bawa, Dinesh Saralaya, Sunil Sharma, Ray Sheridan, Emma C Thomson, Shirley Todd, Chris Twelves, Robert C Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S Nguyen-Van-Tam, Matthew D Snape, Xinxue Liu, Saul N Faust, COV-BOOST study group
Jun 13, 2022
BACKGROUND: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety...
Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation
Adrian M Shields, Sian E Faustini, Harriet J Hill, Saly Al-Taei, Chloe Tanner, Fiona Ashford, Sarita Workman, Fernando Moreira, Nisha Verma, Hollie Wagg, Gail Heritage, Naomi Campton, Zania Stamataki, Mark T Drayson, Paul Klenerman, James ED Thaventhiran, Shuayb Elkhalifa, Sarah Goddard, Sarah Johnston, Aarnoud Huissoon, Claire Bethune, Suzanne Elcombe, David M Lowe, Smita Y Patel, Sinisa Savic, Alex G Richter, Siobhan O Burns, COV-AD consortium
Jun 16, 2022
BACKGROUND: Patients with primary and secondary antibody deficiency are vulnerable to COVID-19 and demonstrate diminished responses following two-dose SARS-CoV-2 vaccine schedules. Third primary vaccinations have been deployed...
SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency
Adrian M Shields, Sian E Faustini, Harriet J Hill, Saly Al-Taei, Chloe Tanner, Fiona Ashford, Sarita Workman, Fernando Moreira, Nisha Verma, Hollie Wagg, Gail Heritage, Naomi Campton, Zania Stamataki, Paul Klenerman, James ED Thaventhiran, Sarah Goddard, Sarah Johnston, Aarnoud Huissoon, Claire Bethune, Suzanne Elcombe, David M Lowe, Smita Y Patel, Sinisa Savic, Siobhan O Burns, Alex G Richter, COV-AD consortium
Aug 25, 2022
BACKGROUND: Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood....
Investigation and Management of Apparently Sporadic Central Nervous System Haemangioblastoma for Evidence of Von Hippel–Lindau Disease
Hugh Furness, Louay Salfity, Johanna Devereux, Dorothy Halliday, Helen Hanson, Deborah M. Ruddy, UK VHL Study Group UK VHL Study Group, Neha Shah, George Sultana, Emma R. Woodward, Richard N. Sandford, Katie M. Snape, Eamonn R. Maher
Sep 17, 2021
Haemangioblastomas are rare, highly vascularised tumours that typically occur in the cerebellum, brain stem and spinal cord. Up to a third of individuals with a haemangioblastoma will have von Hippel–Lindau (VHL) disease....
Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients
Barbara Mühlemann, Charlotte Thibeault, David Hillus, Elisa T Helbig, Lena J Lippert, Pinkus Tober-Lau, Tatjana Schwarz, Marcel A Müller, Pa-COVID-19 collaborative study group, Martin Witzenrath, Norbert Suttorp, Leif E Sander, Christian Drosten, Terry C Jones, Victor M Corman, Florian Kurth
Jul 28, 2021
OBJECTIVES: Dexamethasone has become the standard of care for severe coronavirus disease 2019 (COVID-19), but its virological impact is poorly understood. The objectives of this work were to characterize the kinetics of severe...
Antibody COVID-19 Nucleic Acid Testing Coronavirus disease 2019 (COVID-19) Dexamethasone Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Viral concentration Anti-Inflammatory Agents Antibodies Viral covid-19 Dexamethasone Hospitalization Humans Immunoglobulin A Immunoglobulin G Kinetics Prospective Studies RNA Viral Respiratory System SARS-CoV-2 Seroconversion Viral Load COVID-19 Drug Treatment
A Modified Progressive Supranuclear Palsy Rating Scale.
Marie-Therese Grötsch, Gesine Respondek, Carlo Colosimo, Yaroslau Compta, Jean Christophe Corvol, Joaquim Ferreira, Meret Koroni Huber, Martin Klietz, Lea FM Krey, Johannes Levin, Milica Jecmenica-Lukic, Daniel Macías-García, Wassilios G Meissner, Pablo Mir, Huw Morris, Christer Nilsson, James B Rowe, Klaus Seppi, Maria Stamelou, John C van Swieten, Gregor Wenning, Teodoro del Ser, Lawrence I Golbe, Günter U Höglinger, the ProPSP Study Group, and the Movement Disorder Society-Endorsed PSP Study Group Describe PSP Study Group
Jan 26, 2021
BACKGROUND: The Progressive Supranuclear Palsy Rating Scale is a prospectively validated physician-rated measure of disease severity for progressive supranuclear palsy. We hypothesized that, according to experts' opinion...
Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™
Lisa J Krüger, Julian AF Klein, Frank Tobian, Mary Gaeddert, Federica Lainati, Sarah Klemm, Paul Schnitzler, Ralf Bartenschlager, Berati Cerikan, Christopher J Neufeldt, Olga Nikolai, Andreas K Lindner, Frank P Mockenhaupt, Joachim Seybold, Terry C Jones, Victor M Corman, Nira R Pollock, Britta Knorr, Andreas Welker, Margaretha de Vos, Jilian A Sacks, Claudia M Denkinger, ACE-IT Study Group
Sep 12, 2021
PURPOSE: Rapid antigen-detecting tests (Ag-RDTs) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can transform pandemic control. Thus far, sensitivity (≤ 85%) of lateral-flow assays has limited scale-up....
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP)
James L Alexander, Zhigang Liu, Diana Muñoz Sandoval, Catherine Reynolds, Hajir Ibraheim, Sulak Anandabaskaran, Aamir Saifuddin, Rocio Castro Seoane, Nikhil Anand, Rachel Nice, Claire Bewshea, Andrea D'Mello, Laura Constable, Gareth R Jones, Sharmili Balarajah, Francesca Fiorentino, Shaji Sebastian, Peter M Irving, Lucy C Hicks, Horace RT Williams, Alexandra J Kent, Rachel Linger, Miles Parkes, Klaartje Kok, Kamal V Patel, Julian P Teare, Daniel M Altmann, James R Goodhand, Ailsa L Hart, Charlie W Lees, Rosemary J Boyton, Nicholas A Kennedy, Tariq Ahmad, Nick Powell, VIP study investigators
Oct 12, 2022
BACKGROUND: COVID-19 vaccine-induced antibody responses are reduced in patients with inflammatory bowel disease (IBD) taking anti-TNF or tofacitinib after two vaccine doses. We sought to assess whether immunosuppressive...
Prevalence of RT-qPCR-detected SARS-CoV-2 infection at schools
Peter Willeit, Robert Krause, Bernd Lamprecht, Andrea Berghold, Buck Hanson, Evelyn Stelzl, Heribert Stoiber, Johannes Zuber, Robert Heinen, Alwin Köhler, David Bernhard, Wegene Borena, Christian Doppler, Dorothee von Laer, Hannes Schmidt, Johannes Pröll, Ivo Steinmetz, Michael Wagner
Sep 16, 2021
BACKGROUND: The role of schools in the SARS-CoV-2 pandemic is much debated. We aimed to quantify reliably the prevalence of SARS-CoV-2 infections at schools detected with reverse-transcription quantitative...
Emergency surgery for splenic flexure cancer
Nicola de'Angelis, Eloy Espin, Frederic Ris, Filippo Landi, Bertrand Le Roy, Federico Coccolini, Valerio Celentano, Angela Gurrado, Denis Pezet, Giorgio Bianchi, Riccardo Memeo, Giulio C Vitali, Alejandro Solis, Christine Denet, Salomone Di Saverio, Gian Luigi de'Angelis, Miquel Kraft, Paula Gonzálvez-Guardiola, Aine Stakelum, Fausto Catena, David Fuks, Des C Winter, Mario Testini, Aleix Martínez-Pérez, SFC Study Group
Apr 30, 2021
BACKGROUND: The effectiveness of surgical treatment for splenic flexure carcinomas (SFCs) in emergency settings remains unexplored. This study aims to compare the perioperative and long-term outcomes of different alternatives...
An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment.
Marcus Jepson, Daisy Elliott, Carmel Conefrey, Julia Wade, Leila Rooshenas, Caroline Wilson, David Beard, Jane M Blazeby, Alison Birtle, Alison Halliday, Rob Stein, Jenny L Donovan, CSAW study group, Chemorad study group, POUT study group, ACST-2 study group, OPTIMA prelim study group
Aug 23, 2018
OBJECTIVES: To explore how the concept of randomization is described by clinicians and understood by patients in randomized controlled trials (RCTs) and how it contributes to patient understanding and recruitment. STUDY DESIGN...
Patient information qualitative research randomization Randomized controlled trials Recruitment Recruitment to RCTs Comprehension Decision Making Computer-Assisted Gambling Humans metaphor Patient Education as Topic Patient Selection qualitative research Random Allocation Randomized Controlled Trials as Topic United Kingdom
Final follow-up of the Multicentre Aneurysm Screening Study (MASS) randomized trial of abdominal aortic aneurysm screening.
SG Thompson, HA Ashton, L Gao, MJ Buxton, RAP Scott, Multicentre Aneurysm Screening Study (MASS) Group
Jan 27, 2020
BACKGROUND: The long-term effects of abdominal aortic aneurysm (AAA) screening were investigated in extended follow-up from the UK Multicentre Aneurysm Screening Study (MASS) randomized trial. METHODS: A population-based sample...
Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants.
George W Carnell, Martina Billmeier, Sneha Vishwanath, Maria Suau Sans, Hannah Wein, Charlotte L George, Patrick Neckermann, Joanne Marie M Del Rosario, Alexander T Sampson, Sebastian Einhauser, Ernest T Aguinam, Matteo Ferrari, Paul Tonks, Angalee Nadesalingam, Anja Schütz, Chloe Qingzhou Huang, David A Wells, Minna Paloniemi, Ingo Jordan, Diego Cantoni, David Peterhoff, Benedikt Asbach, Volker Sandig, Nigel Temperton, Rebecca Kinsley, Ralf Wagner, Jonathan L Heeney
Apr 12, 2023
The accelerated development of the first generation COVID-19 vaccines has saved millions of lives, and potentially more from the long-term sequelae of SARS-CoV-2 infection. The most successful vaccine candidates have used the...
neutralising antibodies receptor binding domain (RBD) SARS-CoV-2 antibody pseudotype neutralisation glycan masking Humans Polysaccharides Epitopes Antibodies Neutralizing covid-19 SARS-CoV-2 COVID-19 Vaccines
Published by: Frontiers in immunology
New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA)
Chiara Marvisi, Renato Alberto Sinico, Carlo Salvarani, David Jayne, Domenico Prisco, Benjamin Terrier, Giacomo Emmi, Augusto Vaglio, European EGPA Study Group
May 27, 2020
The European Eosinophilic Granulomatosis with Polyangiitis (EGPA) study group first gathered in Firenze in December 2018. The discussion was centred around the clinical and therapeutic needs in EGPA which still remain unmet....
College Town Working Group Named by Rock Hill and Winthrop
Winthrop University
Jan 01, 0001
Group of 16 will lead initiative to create action plan to boost 'College Town' development around Winthrop campus. Feb. 4 orientation dinner at Winthrop will mark official launch of the initiative.
Published by: Winthrop University
Primary post-transplant lymphoproliferative disorder of the central nervous system
Mary M Taj, Britta Maecker-Kolhoff, Rebecca Ling, Simon Bomken, Birgit Burkhardt, Alan KS Chiang, Monika Csoka, Anna Füreder, Stéphanie Haouy, Jelena Lazic, Natalia Miakova, Veronique Minard-Colin, Suzanne D Turner, Anne Uyttebroeck, Andishe Attarbaschi, the international Berlin-Frankfurt-Münster (i-BFM) Study Group European Intergroup for Childhood Non-Hodgkin’s Lymphoma (EICNHL)
Feb 17, 2021
Primary central nervous system (CNS) post-transplant lymphoproliferative disorder (PTLD) in childhood is rare. Twenty-five patients were retrieved from nine European Intergroup for Childhood Non-Hodgkin's Lymphoma and/or...
Central Nervous System outcome post-transplant lymphoproliferative disorder transplant Treatment Adolescent Adult Allografts Brain Neoplasms Child Child Preschool Disease-Free Survival Female Hematopoietic Stem Cell Transplantation Humans Infant Injections Spinal Lymphoproliferative Disorders Male Organ Transplantation Rituximab Survival Rate
The Max-Min Group Contest
We investigate a group all-pay auction in which each group's effort is represented by the minimum among the effort levels exerted by the group members and the prize is a group-specific public good. We fully characterize the...
SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
Isabella ATM Ferreira, Steven A Kemp, Rawlings Datir, Akatsuki Saito, Bo Meng, Partha Rakshit, Akifumi Takaori-Kondo, Yusuke Kosugi, Keiya Uriu, Izumi Kimura, Kotaro Shirakawa, Adam Abdullahi, Anurag Agarwal, Seiya Ozono, Kenzo Tokunaga, Kei Sato, Ravindra K Gupta, Indian SARS-CoV-2 Genomics Consortium CITIID-NIHR BioResource COVID-19 Collaboration, Genotype to Phenotype Japan (G2P-Japan) Consortium
Jul 29, 2021
The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of...
B.1.617 covid-19 Indian variant SARS-CoV-2 Antibody Escape evasion FITNESS infectivity neutralizing antibodies resistance spike mutation Angiotensin-Converting Enzyme 2 Animals Antibodies Neutralizing Antibodies Viral BNT162 Vaccine covid-19 COVID-19 Vaccines Chlorocebus aethiops HEK293 Cells Humans Immune Evasion india Mutation Protein Binding SARS-CoV-2 Serine Endopeptidases Spike Glycoprotein Coronavirus Vero Cells
The Max-Min Group Contest
We investigate a group all-pay auction in which each group's effort is represented by the minimum among the effort levels exerted by the group members and the prize is a group-specific public good. We fully characterize the...
Demographic, behavioural and occupational risk factors associated with SARS-CoV-2 infection in UK healthcare workers
Daniel James Cooper, Sara Lear, Nyarie Sithole, Ashley Shaw, Hannah Stark, Mark Ferris, CITIID-NIHR BioResource COVID-19 collaboration consortium, John Bradley, Patrick Maxwell, Ian Goodfellow, Michael P Weekes, Shaun Seaman, Stephen Baker
Dec 09, 2022
OBJECTIVE: Healthcare workers (HCWs) are at higher risk of SARS-CoV-2 infection than the general population. This group is pivotal to healthcare system resilience during the COVID-19, and future, pandemics. We investigated...
Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates.
Shengxue Luo, Panli Zhang, Bochao Liu, Chan Yang, Chaolan Liang, Qi Wang, Ling Zhang, Xi Tang, Jinfeng Li, Shuiping Hou, Jinfeng Zeng, Yongshui Fu, Jean-Pierre Allain, Tingting Li, Yuming Zhang, Chengyao Li
Jun 17, 2021
ABSTRACTCOVID-19 vaccines are being developed urgently worldwide. Here, we constructed two adenovirus vectored COVID-19 vaccine candidates of Sad23L-nCoV-S and Ad49L-nCoV-S carrying the full-length gene of SARS-CoV-2 spike...
COVID-19 Vaccines human adenovirus 49 vector mice and non-human primates prime-boost vaccination simian adenovirus 23 vector Adenoviridae Animals Antibodies Neutralizing Antibodies Viral covid-19 COVID-19 Vaccines Female Genetic Vectors HEK293 Cells Humans Immunization Secondary Macaca mulatta Male Mice Mice Inbred BALB C Mice Inbred C57BL SARS-CoV-2 T-Lymphocytes
Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies
Hayley Jones, Ranya Mulchandani, Sian Taylor-Phillips, AE Ades, Justin Shute, Keith Perry, Nastassya Chandra, Tim Brooks, Andre Charlett, Matthew Hickman, Isabel Oliver, Stephen Kaptoge, John Danesh, Emanuele Di Angelantonio, David Wyllie, COMPARE study investigators, EDSAB-HOME investigators
Jul 02, 2021
Background
SARS-CoV-2 antibody tests are used for population surveillance and might have a future role in individual risk assessment. Lateral flow immunoassays (LFIAs) can deliver results rapidly and at scale, but have...
Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR.
Jeremy Ratcliff, Farah Al-Beidh, Sagida Bibi, David Bonsall, Sue Ann Costa Clemens, Lise Estcourt, Amy Evans, Matthew Fish, Pedro M Folegatti, Anthony C Gordon, Cecilia Jay, Aislinn Jennings, Emma Laing, Teresa Lambe, George MacIntyre-Cockett, David Menon, Paul R Mouncey, Dung Nguyen, Andrew J Pollard, Maheshi N Ramasamy, David J Roberts, Kathryn M Rowan, Jennifer Rynne, Manu Shankar-Hari, Sarah Williams, Heli Harvala, Tanya Golubchik, Peter Simmonds, REMAP-CAP Immunoglobulin Domain UK Investigators, and Oxford COVID-19 Vaccine Trial Group AMPHEUS Project
Apr 24, 2022
Tools to detect SARS-CoV-2 variants of concern and track the ongoing evolution of the virus are necessary to support public health efforts and the design and evaluation of novel COVID-19 therapeutics and vaccines. Although...
|
|< |
< |
1 |